
https://www.science.org/content/blog-post/out-old
# Out With the Old (January 2007)

## 1. SUMMARY

This article is a first-person account from a research scientist experiencing a lab shutdown at the start of 2007. The author describes their final days at a research facility, with their official last day approaching at the end of January. They're focused on completing close-out tasks including finishing two papers (Vial Thirty-Three and another manuscript), preparing an interview talk for future employment, clearing their office and lab bench, and handling administrative tasks like signing notebook pages and disposing of old files. The tone captures the bittersweet experience of winding down research work while preparing for an uncertain future, with the physical emptiness of the office serving as a metaphor for the transition.

## 2. HISTORY

This article appeared during a significant period of restructuring in the pharmaceutical and biotechnology industry. The mid-to-late 2000s saw numerous large pharmaceutical companies downsizing their research operations and closing research sites, particularly in the wake of patent cliffs, pipeline failures, and pressure to reduce R&D costs. Many major companies like Pfizer, Merck, GlaxoSmithKline, and AstraZeneca underwent substantial layoffs and site closures between 2005-2010. This trend continued into the 2010s as companies shifted toward more externalized R&D models, collaboration with smaller biotechs, and licensing deals rather than maintaining large internal research infrastructure. The period also coincided with increased consolidation through mergers and acquisitions in the pharma sector.

## 3. PREDICTIONS

The article makes no explicit predictions about biotechnology or pharmaceutical industry trends.

## 4. INTEREST

Rating: **2/10**

This is a personal narrative about a lab closure experience rather than an analytical commentary about biotechnology industry trends, developments, or innovations. While it captures a real aspect of the industry environment in 2007, it lacks the substantive technical or business analysis that would make it valuable for retrospective evaluation of biotechnology predictions or developments.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20070102-out-old.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_